Treatment with PRI-724, a β-catenin/CBP inhibitor, significantly ameliorates hepatic steatosis and fibrosis in MASLD mouse models, evidenced by increased hepatic Marco+Mmp9+Cd68+ KCs and reduced levels of ALT, Mac-2 bp, and fibrotic markers (collagen I/III, α-SMA) (120). The gene discussed is GPT; the disease is metabolic dysfunction-associated steatotic liver disease.